From Our CEO
Drug-resistant infection is a growing threat to health and lives around the world. One way to address this growing, silent pandemic is to share surveillance data among the scientific community. In June 2022, Vivli launched the AMR (antimicrobial resistance) Register to accomplish just this, making it possible for biopharmaceutical companies to share data on infection-causing pathogens for the first time on an online platform.
We were delighted to launch with the support of 7 industry partners, GSK, Johnson & Johnson, Merck, Paratek, Pfizer, Shionogi and Venatorx, sharing datasets from their surveillance programs. The high-quality data offered from these programs was requested by researchers through the AMR Register 39 times in the first year. Many of these unique data have never been shared before.
To encourage further data re-use, we launched the Vivli AMR Surveillance Open Data Re-use Data Challenge, funded by Wellcome, in April 2023. Finalists were announced in the Fall, with the winners receiving monetary awards and expenses to travel to ECCMID 2024, if their research abstract is accepted for presentation.
We look forward to the Register’s second year, with the hope of encouraging more researchers to undertake critical research ventures, including tracking trends in multi-drug resistance over time, predicting future resistance patterns, and informing antibiotic stewardship initiatives.